Non Surgical Intragastric Balloon

Non-Surgical Intragastric Balloon Market Outlook

The global Non-Surgical Intragastric Balloon market is projected to reach USD 1.5 billion by 2035, exhibiting a robust CAGR of 10.5% during the forecast period from 2025 to 2035. This growth is primarily driven by the increasing prevalence of obesity and obesity-related health conditions across the globe, which has heighted the demand for non-invasive weight loss solutions. Furthermore, advancements in medical technology and the introduction of innovative intragastric balloon products have significantly enhanced treatment efficacy and safety profiles, thereby attracting a larger patient demographic. The growing awareness regarding the potential health risks associated with surgical weight loss methods is also contributing to the rising adoption of non-surgical alternatives. In addition, favorable reimbursement policies in various regions are expected to further bolster market growth, providing greater accessibility to patients who require these weight management solutions.

Growth Factor of the Market

The Non-Surgical Intragastric Balloon market is witnessing substantial growth due to several interconnected factors. Firstly, the global rise in obesity rates, influenced by sedentary lifestyles and unhealthy dietary habits, has prompted many individuals to seek effective weight management solutions. Non-surgical methods, particularly intragastric balloons, are increasingly favored due to their non-invasive nature, which reduces recovery time and minimizes complications compared to surgical interventions. Secondly, rigorous clinical studies and trials have underscored the safety and effectiveness of intragastric balloons for weight loss, thus enhancing their credibility among healthcare providers and patients alike. Additionally, the development of advanced balloon designs, such as adjustable and swallowable models, has broadened the applicability of this treatment across various patient profiles. Increased investment by healthcare facilities in patient education and support programs contributes to higher patient adherence and success rates, further promoting the market's growth. Lastly, collaborations between manufacturers and healthcare providers have facilitated better distribution and enhanced patient access to these innovative solutions.

Key Highlights of the Market

• The global Non-Surgical Intragastric Balloon market is expected to achieve a CAGR of 10.5% from 2025 to 2035.
• Single and Dual Intragastric balloons are the leading product types in terms of market share.
• North America dominates the market, driven by high obesity prevalence and advanced healthcare infrastructure.
• Weight Loss application segment accounts for the largest share, reflecting the growing urgency for effective obesity management.
• Silicone balloons are the most utilized material type, favored for their safety and efficacy in clinical applications.

By Product Type

Single Intragastric Balloon:

The Single Intragastric Balloon is a prominent product in the Non-Surgical Intragastric Balloon market, designed to assist patients in weight loss by creating a sense of fullness in the stomach. This type of balloon is typically inserted endoscopically and left in place for six months to a year, providing a temporary weight-loss solution. The effectiveness of the Single Intragastric Balloon is well-documented, with numerous studies confirming significant weight loss among patients within this period. Due to its non-invasive nature and reduced risk of complications compared to surgical alternatives, it has gained popularity among both patients and healthcare providers. Furthermore, its relatively lower cost compared to surgical procedures makes it an appealing choice for many, contributing to its leading market share in the Non-Surgical Intragastric Balloon segment.

Dual Intragastric Balloon:

The Dual Intragastric Balloon is an innovative advancement in the intragastric balloon category, consisting of two balloons that can be inflated simultaneously within the stomach. This design enhances patient satiety more effectively than a single balloon, leading to improved weight loss outcomes. Clinical trials indicate that patients using the Dual Intragastric Balloon experience more significant weight reduction in comparison to those with a single balloon. The dual design also allows for greater flexibility in terms of placement and adjustment, catering to diverse patient needs. As the demand for effective and patient-friendly weight loss solutions grows, the Dual Intragastric Balloon is poised to capture an increasing share of the market due to its enhanced efficacy and patient satisfaction rates.

Triple Intragastric Balloon:

Although not as prevalent as the single and dual balloon types, the Triple Intragastric Balloon is gaining traction in the market. This device consists of three interconnected balloons that expand in the stomach, further enhancing the feeling of fullness. Patients undergoing treatment with the Triple Intragastric Balloon often report substantial weight loss due to the increased volume and pressure created within the stomach, which effectively reduces appetite and food intake. Clinical data suggest that patients using the triple system can achieve superior weight loss results compared to single or dual balloon systems. However, the complexity of insertion and potential discomfort associated with the additional balloons can deter some patients. Nevertheless, the Triple Intragastric Balloon represents a promising option for those seeking aggressive non-surgical weight loss solutions in the evolving obesity treatment landscape.

Adjustable Intragastric Balloon:

The Adjustable Intragastric Balloon offers a unique approach by allowing healthcare providers to adjust the level of inflation post-insertion, tailoring it to the individual needs of the patient. This flexibility is particularly beneficial as it permits ongoing adjustments based on the patient’s progress and comfort levels, enhancing overall treatment efficacy. By utilizing a valve mechanism, the balloon can be inflated or deflated, effectively managing the patient's satiety. This adaptability not only improves patient compliance and satisfaction but also leads to potentially greater weight loss outcomes. As a result, the Adjustable Intragastric Balloon is increasingly sought after for its customization capabilities, positioning it as a significant player in the Non-Surgical Intragastric Balloon market.

Swallowable Intragastric Balloon:

The Swallowable Intragastric Balloon represents a revolutionary advancement in the delivery of intragastric balloon therapy. Unlike traditional methods that require endoscopic insertion, this balloon is designed to be ingested as a capsule and expands in the stomach once swallowed, significantly enhancing the patient experience. The non-invasive, patient-friendly nature of the swallowable balloon eliminates the need for sedation or anesthesia, making it an attractive option for those wary of medical procedures. Initial clinical results suggest that patients can achieve comparable weight loss results to those using traditional balloons. The swallowable balloon is particularly appealing to a younger demographic and those with a fear of invasive procedures, thereby poised to gain traction in the market as awareness and acceptance of this innovative solution grow.

By Application

Weight Loss:

Weight loss is the primary application for Non-Surgical Intragastric Balloons, addressing the urgent need for effective management of obesity and overweight conditions. As obesity rates continue to climb globally, the demand for non-invasive solutions like intragastric balloons is surging. Patients undergoing this treatment often experience significant weight loss, which can lead to a decrease in obesity-related health issues such as diabetes, hypertension, and cardiovascular diseases. The psychological benefits of weight loss also contribute to improved quality of life, enhancing the appeal of this treatment option. Providers are increasingly recommending intragastric balloons as a viable alternative for patients who do not qualify for surgical options or prefer a less invasive method. The growing body of evidence supporting the effectiveness of intragastric balloons in weight management solidifies their role as a leading solution in the obesity treatment landscape.

Obesity Management:

Beyond immediate weight loss, the Non-Surgical Intragastric Balloon is also utilized for ongoing obesity management, serving as a tool to help maintain weight loss achieved through various means. The presence of the balloon creates a sustained sense of fullness, assisting patients in managing their caloric intake over an extended period. This application is particularly essential for individuals who have faced challenges in maintaining weight loss achieved through diet and exercise alone. The ability to support long-term lifestyle changes and provide continuous feedback on eating habits makes intragastric balloons a valuable resource in the broader context of obesity management. Furthermore, the incorporation of behavioral therapy and nutritional counseling alongside balloon therapy enhances the long-term success of weight management efforts.

Metabolic Syndrome Treatment:

The treatment of metabolic syndrome represents an emerging application of Non-Surgical Intragastric Balloons, where the focus extends beyond weight loss to address related health issues such as insulin resistance, dyslipidemia, and hypertension. Research indicates that weight loss achieved through intragastric balloons can significantly improve metabolic markers in affected individuals. By reducing overall body weight and visceral fat, the use of intragastric balloons aids in the mitigation of symptoms associated with metabolic syndrome. This application is garnering attention from healthcare providers looking to offer comprehensive solutions to patients who present with a combination of obesity and metabolic disturbances. As awareness of metabolic syndrome grows, the role of non-surgical interventions, including intragastric balloons, is expected to expand within clinical practice.

Others:

In addition to the primary applications of weight loss and obesity management, Non-Surgical Intragastric Balloons may also be utilized for a range of other purposes, including pre-operative weight reduction for surgical candidates and as part of a multi-modal approach to treat certain conditions linked to obesity. The versatility of intragastric balloons allows them to be integrated into broader treatment protocols, offering patients additional support during their weight loss journey. For instance, healthcare providers may employ intragastric balloons to help manage patients’ weight prior to bariatric surgery, increasing surgical safety and success rates. This multifaceted approach highlights the balloons' capabilities as a component of a holistic strategy aimed at addressing obesity and improving overall health outcomes.

By Distribution Channel

Hospitals:

Hospitals serve as a primary distribution channel for Non-Surgical Intragastric Balloons, providing comprehensive care and support for patients undergoing this treatment. The hospital setting is often equipped with advanced medical facilities and expertise in endoscopic procedures, making it a preferred choice for balloon insertion and patient monitoring. The presence of multidisciplinary teams, including surgeons, nutritionists, and psychologists, further enhances the level of care available to patients. Additionally, hospitals tend to have established relationships with leading intragastric balloon manufacturers, ensuring access to the latest products and technologies. As the demand for non-surgical weight loss options increases, hospitals are refining their protocols and expanding services to accommodate more patients, thereby solidifying their role as a dominant distribution channel.

Ambulatory Surgical Centers:

Ambulatory Surgical Centers (ASCs) are emerging as increasingly popular venues for the insertion of Non-Surgical Intragastric Balloons due to their focus on providing same-day surgical care. These facilities are often more cost-effective than traditional hospitals, allowing for competitive pricing that appeals to budget-conscious patients. ASCs typically offer a streamlined process for balloon insertion and post-operative care, resulting in reduced wait times and enhanced patient convenience. The specialized nature of ASCs allows them to provide tailored services focused on weight loss procedures, which is appealing to patients seeking dedicated support. Furthermore, the increasing collaboration between balloon manufacturers and ASCs is facilitating improved access to innovative products, thereby driving growth within this distribution channel.

Specialty Clinics:

Specialty clinics have become crucial players in the Non-Surgical Intragastric Balloon market, capitalizing on their focused expertise in weight management and obesity treatments. These clinics typically offer a comprehensive suite of services, including nutritional counseling, psychological support, and post-balloon monitoring, creating a holistic approach to weight loss. Patients often prefer specialty clinics for their personalized care and dedicated resources, which can enhance adherence to treatment protocols. The expertise of healthcare professionals in these settings contributes to higher success rates and improved patient outcomes. As public awareness of non-surgical weight loss options grows, specialty clinics are likely to see increased patient referrals and expansion opportunities, reinforcing their significance in the distribution landscape.

Others:

Other distribution channels for Non-Surgical Intragastric Balloons may include online platforms, telemedicine consultations, and direct sales to healthcare providers. The rise of eHealth and telehealth services has expanded access to weight management solutions, allowing patients to consult with specialists even if they are geographically distant from major healthcare facilities. This accessibility is particularly crucial for individuals living in rural or underserved areas. Additionally, the potential for direct-to-provider sales enables manufacturers to establish connections with smaller clinics and private practices offering intragastric balloon services. Overall, these alternative distribution channels are broadening the reach of Non-Surgical Intragastric Balloons, making them more accessible to diverse patient populations.

By Material Type

Silicone Balloons:

Silicone balloons dominate the material type segment of the Non-Surgical Intragastric Balloon market, primarily due to their biocompatibility and durability. Silicone is known for its ability to withstand stomach acids and maintain structural integrity over extended periods, ensuring consistent performance during treatment. The smooth surface of silicone balloons minimizes the risk of irritation to the gastric lining, enhancing patient comfort and reducing potential complications. Furthermore, clinical studies have shown that silicone balloons contribute to significant weight loss outcomes, solidifying their status as a preferred choice among healthcare providers. As the demand for effective, safe weight loss solutions continues to grow, silicone-based intragastric balloons are expected to maintain their leading market share.

Saline-Filled Balloons:

Saline-filled balloons represent another prominent material type within the Non-Surgical Intragastric Balloon market, characterized by a unique fill composition that provides a distinct weight loss mechanism. These balloons are inflated with saline water, which allows for a controlled level of volume within the stomach, contributing to satiety. The saline solution also acts as a safety feature; in the event of balloon rupture, it can be absorbed naturally by the body. Saline-filled balloons have gained traction among patients who prioritize safety and ease of use, as the non-toxic nature of saline minimizes potential risks. As more patients seek non-invasive options for weight management, the demand for saline-filled balloons is anticipated to rise.

Gas-Filled Balloons:

Gas-filled balloons are a less common material type in the Non-Surgical Intragastric Balloon market but offer unique advantages in terms of ease of insertion and patient comfort. By utilizing a gas inflating mechanism, these balloons can achieve a lighter overall weight and a larger volume within the stomach, promoting a substantial feeling of fullness. However, the risk of gas diffusion and expansion may pose challenges, necessitating careful monitoring and management by healthcare providers. Despite these concerns, gas-filled balloons are gaining interest among patients seeking innovative and effective solutions for weight management. The evolving landscape of intragastric balloon technology suggests a potential for growth in this segment as manufacturers refine their designs and address existing limitations.

Others:

Other material types in the Non-Surgical Intragastric Balloon market may include newer biomaterials or novel composites designed for enhanced performance. Continuous research and development efforts are focused on improving the safety, durability, and efficacy of intragastric balloons by exploring alternative materials that may offer distinct benefits. Innovations in balloon design, such as incorporating antimicrobial properties or enhanced structural support, are also being investigated. As the industry progresses, these alternative materials may emerge as viable options, creating a more diverse selection within the Non-Surgical Intragastric Balloon market and catering to the varying needs of patients and healthcare providers alike.

By Region

The North American region is currently the largest market for Non-Surgical Intragastric Balloons, accounting for approximately 40% of the global market share. This dominance can be attributed to the high prevalence of obesity and obesity-related health problems within the population, driving the demand for innovative weight loss solutions. The established healthcare infrastructure and advanced medical facilities in the United States and Canada further facilitate the adoption of intragastric balloon therapies. Moreover, the increased focus on patient education and awareness programs has significantly contributed to the growth of this market segment. With a CAGR of 11% projected for this region, North America remains a critical player in the Non-Surgical Intragastric Balloon market.

In contrast, the Asia Pacific region is emerging as a rapidly growing market for Non-Surgical Intragastric Balloons, with a CAGR of 12% expected over the forecast period. Factors driving this growth include the rising prevalence of obesity, changing dietary patterns, and growing health consciousness among consumers. Countries such as China, India, and Australia are witnessing increased adoption of non-surgical weight management solutions, including intragastric balloons. The expanding middle-class population in these countries is seeking effective weight loss options, further propelling market expansion. As healthcare facilities and providers enhance their capabilities to offer innovative weight management solutions, Asia Pacific is poised to become a significant contributor to the overall Non-Surgical Intragastric Balloon market.

Opportunities

The Non-Surgical Intragastric Balloon market presents numerous opportunities for growth, particularly in light of the increasing emphasis on preventive healthcare and wellness. As obesity rates continue to rise globally, healthcare providers and policymakers are exploring innovative solutions to address the obesity epidemic. This shift in focus creates a favorable environment for the expansion of non-surgical weight management options, including intragastric balloons. Furthermore, rising health awareness among consumers is leading to increased willingness to invest in weight loss solutions that promote overall health and wellness. Companies specializing in intragastric balloon technology have the potential to capitalize on this trend by developing targeted marketing strategies and educational programs that emphasize the long-term health benefits of non-surgical interventions. This proactive approach can enhance patient engagement and drive adoption.

Another significant opportunity lies in the expansion of distribution channels to reach untapped markets. The growth of telehealth services and online consultations presents a unique avenue for manufacturers and healthcare providers to connect with patients seeking weight management solutions. By leveraging technology, companies can enhance access to non-surgical interventions, particularly for individuals in rural or underserved regions. Additionally, partnerships with specialty clinics and ambulatory surgical centers can facilitate quicker access to intragastric balloon therapies, further broadening their market reach. As the healthcare landscape continues to evolve, the ability to adapt to changing consumer preferences and leverage innovative distribution strategies will be crucial for success in the Non-Surgical Intragastric Balloon market.

Threats

While the Non-Surgical Intragastric Balloon market shows promising growth prospects, several threats may hinder its progress. One such threat is the potential for regulatory challenges and scrutiny regarding the safety and efficacy of intragastric balloon treatments. As the market expands and new products are introduced, regulatory bodies may impose stricter guidelines and testing requirements, which could slow down the approval process for innovative solutions. Additionally, any negative publicity or adverse events associated with intragastric balloon procedures could lead to increased public skepticism and reduced patient confidence in these treatments. The need for continuous monitoring, rigorous clinical trials, and transparent reporting will be paramount in mitigating these risks and maintaining credibility within the market.

Another significant threat to the Non-Surgical Intragastric Balloon market is the emergence of alternative weight loss solutions and advanced surgical techniques. The rapid development of technologies such as minimally invasive surgical procedures and weight loss drugs may divert patient interest away from non-surgical interventions. As patients become more educated about their options, they may opt for alternatives that promise quicker results or fewer complications. Consequently, manufacturers and healthcare providers must remain agile and responsive to emerging trends in the weight loss landscape, continually refining their offerings to maintain competitiveness. Emphasizing the advantages of non-surgical options, such as lower risks and shorter recovery times, will be essential to countering this competitive threat.

Competitor Outlook

• Apollo Endosurgery, Inc.
• Obalon Therapeutics, Inc.
• Spatz Medical, Inc.
• Endoscopy Division of Boston Scientific Corporation
• ReShape Lifesciences Inc.
• Medtronic plc
• Allurion Technologies, Inc.
• Gastric Balloon Technologies, Inc.
• SentreHEART, Inc.
• Intragastric Balloon Company
• Enteromedics Inc. (now known as ReShape Lifesciences)
• Inflation Technologies Group
• Baricol, Inc.
• Gastric Implants
• Obesity Medical Association (OMA)

The competitive landscape of the Non-Surgical Intragastric Balloon market is characterized by a mix of established players and emerging companies, each striving to innovate and capture market share. Major manufacturers are focusing on research and development to enhance the safety and efficacy of their products, while also investing in patient education and support programs to encourage adherence to treatment protocols. Strategic partnerships and collaborations between manufacturers and healthcare providers are becoming increasingly common, as these alliances can facilitate better distribution, access to advanced technologies, and improved patient outcomes. Furthermore, companies are actively exploring international markets to expand their reach and address the growing global demand for non-surgical weight management solutions.

Key companies in the market, such as Apollo Endosurgery, Inc., are recognized for their pioneering intragastric balloon products and extensive experience in the field of bariatric interventions. Apollo's ORBERA™ intragastric balloon system has established itself as a leading treatment option, backed by rigorous clinical studies demonstrating its effectiveness in aiding weight loss and improving metabolic health. Similarly, Obalon Therapeutics, Inc. has made significant strides with its swallowable intragastric balloon technology, which provides a patient-friendly alternative to traditional balloon insertion methods. The company's innovative approach has garnered attention and driven demand for their products in the weight loss segment.

Medtronic plc, known for its diverse medical device portfolio, is also a prominent player in the Non-Surgical Intragastric Balloon market. The company has capitalized on its extensive distribution network and existing relationships with healthcare providers to introduce its intragastric balloon systems effectively. Its commitment to innovation and patient-centric solutions positions Medtronic favorably within this competitive landscape. Furthermore, ReShape Lifesciences Inc. has gained recognition for its comprehensive weight management solutions that combine intragastric balloons with behavioral therapy and nutritional support, reflecting a holistic approach to obesity treatment. The ability of these key players to adapt to changing market dynamics and patient needs will be critical as the Non-Surgical Intragastric Balloon market continues to evolve.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 Baricol, Inc.
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 Medtronic plc
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 Gastric Implants
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 SentreHEART, Inc.
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Spatz Medical, Inc.
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Apollo Endosurgery, Inc.
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Obalon Therapeutics, Inc.
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 ReShape Lifesciences Inc.
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Allurion Technologies, Inc.
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Inflation Technologies Group
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Intragastric Balloon Company
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Obesity Medical Association (OMA)
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Gastric Balloon Technologies, Inc.
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Endoscopy Division of Boston Scientific Corporation
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Enteromedics Inc. (now known as ReShape Lifesciences)
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Non Surgical Intragastric Balloon Market, By Application
    • 6.1.1 Weight Loss
    • 6.1.2 Obesity Management
    • 6.1.3 Metabolic Syndrome Treatment
    • 6.1.4 Others
  • 6.2 Non Surgical Intragastric Balloon Market, By Product Type
    • 6.2.1 Single Intragastric Balloon
    • 6.2.2 Dual Intragastric Balloon
    • 6.2.3 Triple Intragastric Balloon
    • 6.2.4 Adjustable Intragastric Balloon
    • 6.2.5 Swallowable Intragastric Balloon
  • 6.3 Non Surgical Intragastric Balloon Market, By Material Type
    • 6.3.1 Silicone Balloons
    • 6.3.2 Saline-Filled Balloons
    • 6.3.3 Gas-Filled Balloons
    • 6.3.4 Others
  • 6.4 Non Surgical Intragastric Balloon Market, By Distribution Channel
    • 6.4.1 Hospitals
    • 6.4.2 Ambulatory Surgical Centers
    • 6.4.3 Specialty Clinics
    • 6.4.4 Others

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Middle East & Africa - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 Middle East
      • 10.5.1.2 Africa
  • 10.6 Non Surgical Intragastric Balloon Market by Region

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Non Surgical Intragastric Balloon market is categorized based on

By Product Type

• Single Intragastric Balloon
• Dual Intragastric Balloon
• Triple Intragastric Balloon
• Adjustable Intragastric Balloon
• Swallowable Intragastric Balloon

By Application

• Weight Loss
• Obesity Management
• Metabolic Syndrome Treatment
• Others

By Distribution Channel

• Hospitals
• Ambulatory Surgical Centers
• Specialty Clinics
• Others

By Material Type

• Silicone Balloons
• Saline-Filled Balloons
• Gas-Filled Balloons
• Others

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Apollo Endosurgery, Inc.
• Obalon Therapeutics, Inc.
• Spatz Medical, Inc.
• Endoscopy Division of Boston Scientific Corporation
• ReShape Lifesciences Inc.
• Medtronic plc
• Allurion Technologies, Inc.
• Gastric Balloon Technologies, Inc.
• SentreHEART, Inc.
• Intragastric Balloon Company
• Enteromedics Inc. (now known as ReShape Lifesciences)
• Inflation Technologies Group
• Baricol, Inc.
• Gastric Implants
• Obesity Medical Association (OMA)